123158-68-9 Usage
General Description
3-Bromo-5-ethyl-benzenamine, also known as 3-bromo-5-ethyl-aniline, is an organic compound with the chemical formula C8H10BrN. It is a derivative of aniline, featuring a bromine atom at the 3 position and an ethyl group at the 5 position of the benzene ring. This chemical is primarily used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also utilized in the production of dyes, pigments, and other fine chemicals. 3-Bromo-5-ethyl-benzenamine is a colorless to pale yellow liquid with a faint amine odor and is considered to be reasonably stable under normal conditions. It is important to handle this chemical with care as it may cause skin and eye irritation, and its inhalation should be avoided.
Check Digit Verification of cas no
The CAS Registry Mumber 123158-68-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,3,1,5 and 8 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 123158-68:
(8*1)+(7*2)+(6*3)+(5*1)+(4*5)+(3*8)+(2*6)+(1*8)=109
109 % 10 = 9
So 123158-68-9 is a valid CAS Registry Number.
InChI:InChI=1/C8H10BrN/c1-2-6-3-7(9)5-8(10)4-6/h3-5H,2,10H2,1H3
123158-68-9Relevant articles and documents
NMDA antagonists
-
, (2008/06/13)
The present invention is directed to a new class of 4-sulfanimide-quinoline derivatives and to their use as NMDA antagonists.
Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders
-
, (2008/06/13)
4-Oxo-1,4-dihydroquinoline compounds having a 2-acidic group or a group convertible thereto in vivo, and their pharmaceutically acceptable salts, are potent specific antagonists of N-methyl-D-aspartate (NMDA) receptors and are therefore useful in the treatment of neurodegenerative disorders. 4-Oxo-1,4-dihydroquinoline compounds having a 2-acidic group or a group convertible thereto in vivo, other than carboxy or C 1-6 alkoxycarbonyl, are novel compounds, as also are compounds of formula II STR1 wherein R 2 represents carboxy or a group convertible thereto in vivo, R 6 is hydrogen and R 5 and R 7 represent C 1-6 alkyl or halogen, provided that R 5 and R 7 are not simultaneously chlorine or simultaneously bromine; a process for preparing the novel compounds is described, as also are pharmaceutical compositions containing the novel compounds.